Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer-Reference-Cited by-同舟云学术

Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer

Published:2022-07-22 Issue:29 Volume:101 Page:e29532
ISSN:1536-5964
Container-title:Medicine
language:en
Short-container-title:

Author:

Iede Kiyotsugu,Yamada Terumasa,Ueda Masami,Tsuda Yujiro,Nakashima Shinsuke,Ohta Katsuya,Tanida Tsukasa,Matsuyama Jin,Ikenaga Masakazu,Tominaga Shusei

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference24 articles.

1. Multiple liver metastases rather than the presence of liver metastasis is a significantly poor prognostic factor for patients with advanced pancreatic cancer;Iede;Pancreas,2020

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

4. Drug repurposing: progress, challenges and recommendations;Pushpakom;Nat Rev Drug Discov,2019

5. Angiotensin blockade therapy and survival in pancreatic cancer: a population study;Keith;BMC Cancer,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prevalence and impact of overweight and hypertension among patients with pancreatic cancer;Oncology in Clinical Practice;2024-03-05

2. Clinical Significance of Increased Skeletal Muscle Mass During Nab-Paclitaxel Plus Gemcitabine Treatment in Patients With Advanced Pancreatic Cancer;Pancreas;2023-12-28

3. Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer;Medicine;2022-08-26

4. Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer;Medicine;2022-08-26